Skip to main content
. Author manuscript; available in PMC: 2020 Aug 14.
Published in final edited form as: Stem Cells. 2018 Nov 12;36(12):1804–1815. doi: 10.1002/stem.2909

Figure 7.

Figure 7.

The BRG1 inhibitor PFI-3 sensitizes GICs to chemotherapy. (A): X16 GICs were treated with TMZ (500 μM) and PFI-3 (1 μM), and cell proliferation was determined by CellTiter-Glo assays. (B): Protein lysates from X16 GICs treated with PFI-3 were immunoblotted for GFAP and actin. (C): X10 GICs were treated with TMZ (500 μM) and PFI-3 (1 μM), and cell proliferation was determined by CellTiter-Glo assays. (D): X10 and X16 GICs were treated with carmustine (10 μM) and PFI-3 (1 μM), and CellTiter-Glo assays performed. *p ≤ .05 was considered to be statistically significant.